DEC-15-2003 15:44

©~/

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (CURRENTLY AMENDED) A method of decreasing a cytokine mediated hepatic injury response in a mammal comprising administering the peptide shown in SEQ ID NO:1 to the mammal in a pharmaceutically acceptable formulation at a dose and duration to decrease a cytokine mediated hepatic injury response.

3 2: (ORIGINAL) The method of claim 4 wherein said compound is administered prior to said response.

d. (ORIGINAL) The method of claim 1 wherein said compound is administered subsequent to said response.

A. (ORIGINAL) The method of claim 1 wherein said compound is administered substantially concurrently with said response.

が (ORIGINAL) The method of claim 1 wherein said compound is administered in the formulation selected from the group consisting of a solution, an emulsion and a suspension.

VO

8. (ORIGINAL) The method of claim 1 wherein said compound is administered parenterally.

(ORIGINAL) The method of claimy wherein said compound is administered at a concentration in the range of about 0.5 mg/kg to about 20 mg/kg.

8. (CURRENTLY AMENDED) A method for treating hepatic injury in a mammal caused by a chemical toxin comprising administering a pharmaceutically effective concentration of the peptide shown in SEQ ID NO:1 for a duration to treat hepatic injury caused by the chemical toxin.

9. (ORIGINAL) The method of claim 8 wherein the chemical toxin is selected from the group consisting of ethanol, lead, cadmium, carbon tetrachloride, and acetaminophen.

infection related hepatic injury in a mammal comprising administering a

pharmaceutically effective concentration of the peptide shown in SEQ ID NO:1 for a

duration to treat hepatic injury related to the bacterial or viral infection.

The method of claim 10 wherein the bacterial or viralinfection is caused by an organism selected from the group consisting of
Staphylococcus species, Streptococcus species, Neisseria species, Salmonella

species, Shigella species, Escherichia coli, Clostridium perfringens, Klebsiella species, Proteus species, Enterobacter species, Bacteroides species, Brucella species, Francisella tularensis, Listeria monocytogenes, Acinetobacter species, Streptobacillus moniliformis, Vibrio species, Helicobacter pylori, Pseudomonas species, Haemophilus species, Bordetella pertussis, influenza viruses, adeneviruses, paramyxoviruses, rubella viruses, polioviruses, hepatitis viruses, herpesviruses, rabies viruses, human inhunodeficiency-viruses-and-papilloma-viruses.

12. (NEW) The method of claim 1 wherein said compound is administered at least until hepatic function normalizes.